CARI III Inhibits Tumor Growth in a Melanoma-Bearing Mouse Model through Induction of G0/G1 Cell Cycle Arrest
- Authors
- Park, Hye-Jin
- Issue Date
- Sep-2014
- Publisher
- MDPI
- Keywords
- mushroom mixture; CARI III; melanoma; G0/G1 cell cycle arrest; anti-cancer; cyclin D1; CDK4; CDK2
- Citation
- MOLECULES, v.19, no.9, pp.14383 - 14395
- Journal Title
- MOLECULES
- Volume
- 19
- Number
- 9
- Start Page
- 14383
- End Page
- 14395
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12362
- DOI
- 10.3390/molecules190914383
- ISSN
- 1420-3049
- Abstract
- Mushroom-derived natural products have been used to prevent or treat cancer for millennia. In this study, we evaluated the anticancer effects of CARI (Cell Activation Research Institute) III, which consists of a blend of mushroom mycelia from Phellinus linteus grown on germinated brown rice, Inonotus obliquus grown on germinated brown rice, Antrodia camphorata grown on germinated brown rice and Ganoderma lucidum. Here, we showed that CARI III exerted anti-cancer activity, which is comparable to Dox against melanoma in vivo. B16F10 cells were intraperitoneally injected into C57BL6 mice to develop solid intra-abdominal tumors. Three hundred milligrams of the CARI III/kg/day p. o. regimen reduced tumor weight, comparable to the doxorubicin (Dox)-treated group. An increase in life span (ILS% = 50.88%) was observed in the CARI III-administered group, compared to the tumor control group. CARI III demonstrates anti-proliferative activity against B16F10 melanoma cells through inducing G0/G1 cell cycle arrest. CARI III inhibits the expression of cyclin D1, CDK4 and CDK2 and induces p21. Therefore, CARI III could be a potential chemopreventive supplement to melanoma patients.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 바이오나노대학 > 식품생물공학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12362)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.